FDA Grants Approval of New Pediatric Glioma Drug to Day One, a Biopharma Co-founded by CureSearch Board Member Dr. Samuel Blackman
Pediatric low-grade glioma (pLGG) is the most common form of pediatric brain cancer. Day One’s OJEMDA™ is the first targeted treatment for pLGG tumors with BRAF fusions and mutations. Last week, on April 23, 2024, Day One Biopharmaceuticals was granted Accelerated […]
